Novartis AG EBIT

As of the most recent data (June 2026), NVS shows a EBIT of $17B. That compares with $17B in the prior-year period — up 2.3% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NVS's EBIT is now $17B (was $17B) — a 2.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novartis AG is outperforming or lagging.

The Healthcare sector average EBIT is about $110B. Novartis AG is at $17B, which is lower that average. That is roughly 84.0% below the sector mean. Use the comparison chart on this page to see how NVS stacks up against individual peers as well.

Tracking NVS's ebit over time shows whether Novartis AG is scaling, shrinking, or reshaping that part of the business. The current reading is $17B That compares with $17B in the prior-year period — up 2.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Novartis AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $17B) with ownership activity and broader fundamentals.